FDA Authority To Force Antihistamine Switch Denounced By Pfizer Chief
This article was originally published in The Tan Sheet
Executive Summary
FDA lacks the statutory power to force a prescription antihistamine to switch OTC, Pfizer CEO Henry McKinnell insisted during an analysts call April 18.
You may also be interested in...
New Rx Antihistamines Free From Cardio Risks Of Predecessors - JAPhA
Newer second-generation antihistamines are safer than older Rx drugs discontinued for safety reasons, a commentary in the May/June Journal of the American Pharmaceutical Association asserts.
New Rx Antihistamines Free From Cardio Risks Of Predecessors - JAPhA
Newer second-generation antihistamines are safer than older Rx drugs discontinued for safety reasons, a commentary in the May/June Journal of the American Pharmaceutical Association asserts.
Antihistamine OTC Switch: FDA Asking If Rx Products Have "Unique" Aspects
FDA regards the safety profiles of Rx antihistamines Claritin, Allegra and Zyrtec to be at least as good as currently marketed OTC antihistamines, briefing documents for the upcoming May 11 advisory committee meeting indicate.